Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.
about
HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responsesReplicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutationHigh-level HIV-1 Nef transient expression in Nicotiana benthamiana using the P19 gene silencing suppressor protein of Artichoke Mottled Crinckle VirusHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.SIVsm Tat, Rev, and Nef1: functional characteristics of r-GV internalization on isotypes, cytokines, and intracellular degradation.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsCross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope GlycoproteinsSystemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.T-cell and neuronal apoptosis in HIV infection: implications for therapeutic intervention.Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunizationHeterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.Problems and emerging approaches in HIV/AIDS vaccine development.Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case studyRole of adjuvants in modeling the immune response.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis.
P2860
Q24564896-A37A415F-B612-4911-95A5-C53CA1FCB33BQ24798257-47FF7C9C-FE6F-433B-9625-885AD3B74769Q28265405-D380AD1E-9D37-47B6-9915-FDDD36BBE6DFQ30381447-D4A0A822-05CB-4717-AD66-B7F11E4EB4BFQ33571825-30025A37-5C12-41A6-9A6C-B3E8603908DBQ33636080-6C9F4D08-4C4B-4950-8F32-AD1B3E341A13Q33737723-D59B9ACB-4B9A-4989-8FD1-5BF3D0FF3781Q33960361-CB69B263-DD41-4C36-9A38-86F4F330E2F8Q34546037-DCBCCBED-1ED9-4E56-B13D-CEB1644412CAQ35613792-D6B5F5F2-0B35-4263-809E-0535398658E9Q35621704-90F32D08-2015-421A-B5DE-7352ED41C828Q35828002-39D8507D-498E-4591-85D4-51F49302EFFCQ36162593-D512EE97-7ACE-48AB-8EE6-54200B1C0851Q36539997-BB53E7EF-09AA-45D9-8233-72864CD7FF6CQ36758574-03BA0638-E7DD-4C11-8695-31CC9E1FAA92Q37009569-0DEE5A70-2866-4001-90C8-B74DDDF5865DQ37377681-9AF1793B-BD59-40F2-9321-8F5421A2368CQ37803320-921C38C0-4D0C-4977-958E-EAF6B4DE79EEQ37812128-342CA9E1-2166-4968-A8B1-A15629624270Q40273841-4879BCE7-74AE-4072-B128-7B7AB955CEAEQ41860986-8C519A13-E0A8-4609-A71D-5570433958D1
P2860
Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Prevention of disease induced ...... ulticomponent protein vaccine.
@en
Prevention of disease induced ...... ulticomponent protein vaccine.
@nl
type
label
Prevention of disease induced ...... ulticomponent protein vaccine.
@en
Prevention of disease induced ...... ulticomponent protein vaccine.
@nl
prefLabel
Prevention of disease induced ...... ulticomponent protein vaccine.
@en
Prevention of disease induced ...... ulticomponent protein vaccine.
@nl
P2093
P2860
P50
P1433
P1476
Prevention of disease induced ...... ulticomponent protein vaccine.
@en
P2093
Claudine Bruck
Gerald Voss
Kelledy Manson
Michael Wyand
P2860
P304
P356
10.1128/JVI.77.2.1049-1058.2003
P407
P577
2003-01-01T00:00:00Z